Statins and Vitamin D

American Journal of Cardiology

Volumn 100, Issue 8, 2007, Pages 1329-

  Aloia, John F ^a   Li Ng, Melissa ^a   Pollack, Simcha ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; COLECALCIFEROL; PLACEBO;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFECT; FRACTURE; HIP FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME; VITAMIN D;

EID: 34848914821     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.05.024     Document Type: Letter

References (10)

1. Pérez-Castrillón J.L., Vega G., Abad L., Sanz A., Chaves J., Hernandez G., and Dueñas A. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99 (2007) 903-905
2. Aloia J.F., Talwar S.A., Pollack S., and Yeh J. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med 165 (2005) 1618-1623
3. Hatzigeorgiou C., and Jackson J.L. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16 (2005) 990-998
4. Maeda T., Matsunuma A., Kurahashi I., Yanagawa T., Yoshida H., and Horiuchi N. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92 (2004) 458-471
5. Kaji H., Kanatani M., Sugimoto T., and Chihara K. Statins modulate the levels of osteoprotegerin/receptor activator of NFÊB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 37 (2005) 589-592
6. Wilczek H., Sobra J., Ceska R., Justová V., Jùzová Z., Procházková R., and Kvasilová M. Monitoring plasma levels of vitamin D metabolites in simvastatin therapy in patients with familial hypercholesterolemia. Cas Lek Cesk (Czeck) 133 (1994) 727-729
7. Wilczek H., Sobra J., Justova V., and Ceska R. Iatropathogenic effect of Mevacor on vitamin D metabolism. Cas Lek Cesk (Czeck) 128 (1989) 1254-1256
8. Montagnani M., Loré F., Di Cairano G., Gonnelli S., Ciuoli C., Montagnani A., and Gennari C. Effects of pravastatin treatment on vitamin D metabolites. Clin Ther 16 (1994) 824-829
9. Ismail F., Corder C.N., Epstein S., Barbi G., and Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther 12 (1990) 427-430
10. Dobs A.S., Levine M.A., and Margolis S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism 40 (1991) 524-528